Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies: A Multicenter, Single-Arm, Phase II Study With Multiple Cohorts

NCT07309770 is registered in ClinicalTrials.gov with Sheng Zhang as lead sponsor.

NCT NCT07309770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07309770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Trastuzumab Rezetecan in Advanced Solid Tumors Refractory to Standard Therapies: A Multicenter, Single-Arm, Phase II Study With Multiple Cohorts
Lead sponsor
Sheng Zhang
Phase
Phase 2
Overall status
Recruiting
Start date
December 18, 2025
Completion date
March 11, 2028
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor cancer, antibody-drug conjugates, urachal cancer